Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2017-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2017年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as "普洛药业股份有限公司 2017 年半年度报告摘要" which translates to "Pu Luo Pharmaceutical Co., Ltd. 2017 Semi-Annual Report Summary." It contains detailed financial data for the half-year period of 2017, including revenue, net profit, earnings per share, and asset information. It also discusses operational highlights, management analysis, and changes in accounting policies. The document is a comprehensive financial report for a period shorter than a full fiscal year (half-year). The length is 4474 characters, which is consistent with a summary of an interim report rather than a brief announcement. It contains substantive financial data and analysis, not just a reference or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-27 Chinese
2017年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2017 半年度报告全文" which translates to "2017 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, financial indicators, and other comprehensive information typical of an interim or quarterly report. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data for the half-year period. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-27 Chinese
第七届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board of 普洛药业股份有限公司 regarding the approval of the 2017 half-year report and a change in accounting policy. It is dated August 25, 2017, and includes voting results. The document is short (475 characters) and primarily announces the approval of the half-year report rather than containing the report itself. According to the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not contain substantive financial data or the full report.
2017-08-27 Chinese
2017年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2017 年半年度报告全文" which translates to "2017 Semi-Annual Report Full Text." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity. The report explicitly states it is a half-year financial report for 2017, with comprehensive financial data and analysis. It is not a brief announcement or a certification but a full financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-27 Chinese
第七届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 普洛药业股份有限公司 regarding the approval of the 2017 semi-annual report and a change in accounting policy. It includes voting results and confirms the meeting was held according to legal and company regulations. The document is short (473 characters) and primarily announces the board's decisions rather than providing the full semi-annual report itself. Therefore, it is not the interim/quarterly report (IR) itself but an announcement of board/management decisions. This fits best under Board/Management Information (MANG) as it relates to board meeting resolutions and decisions.
2017-08-27 Chinese
关于控股股东及其一致行动人累计增持本公司股份达2%的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the cumulative increase in shareholding by the controlling shareholder and its concerted parties, specifying the percentage increase in shares held and compliance with relevant laws and regulations. It details the share purchase transactions, legal opinions on the legitimacy of the shareholding increase, and confirms adherence to disclosure obligations. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds.
2017-07-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.